Bristol-Myers Squibb has agreed to buy the cancer specialist just two months after its series B round, in a deal that will involve $800m in cash upfront.

Alzheimer's drug developer Heptares has been acquired by pharmaceutical company Sosei, providing exits to corporate backers Novartis and Takeda.

Seagate-backed customised silicon device maker Easic aims to float on Nasdaq after raising $120m in venture funding.

The Israel-based solar inverter maker, which counts Norwest Venture Partners and GE Capital as backers, intends to float on Nasdaq.

Itochu and Mitsubishi UFJ both exited the online flash sales company in a $14.8m purchase by internet company Mixi.

Samsung acquired the mobile commerce technology provider for an undisclosed sum, giving exits to Visa and General Electric subsidiary Synchrony Financial.

MedImmune-backed Inotek, which is working on treatments for glaucoma, priced its IPO at $6a share and is set to secure an additional $20m in convertible debt.

Invitae, a genetic testing technology spin-out from Genomic Health, had initially raised $101.6m when it floated last week.

The agricultural biotechnology developer had raised $101m from investors including chemical producer BASF.

The Siemens-backed cancer treatment company, which has raised $195m in funding, will look to raise up to $69m when it floats on Nasdaq.